Friday, August 24, 2018 2:18:52 PM
https://finance.yahoo.com/news/shareholder-creative-medical-technology-holdings-214300226.html
Just in case people can't click the link, I'll post it below.
PHOENIX, Aug. 14, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities.
Debt: Since our last 8k on debt reduction an additional $268,858.00 has been extinguished.
CaverStemTM: Domestic recruitment, vetting and training of physicians on the CaverStemTM program for the use of the patients own stem cells for the treatment of erectile dysfunction is continuing post AUA Conference in May 2018.
We wish to welcome some of the physicians in the CaverStem program;
Elias Said, MD and Mark Bieri, MD located in Las Cruces, NM. (caverstem-nm.com)
Victor Liu, MD located in San Francisco, CA, (caverstem-sanfrancisco.com)
David Brown, MD located in San Diego, CA, (caverstem-sandiego.com)
Barton Wachs, MD located in Orange County, CA, (caverstem-oc.com)
Sheldon Freedman, MD located in Las Vegas, CA, (caverstem-lasvegas.com)
Perinchery Narayan, MD at North Florida Urology with offices in Orlando, Ocala, Gainsville, St. Augustine and Palatka, FL. (caverstem-northflorida.com)
CaverStemTM International:
Implementation of our contract with Promo Med continues to move forward. We are also currently working with Dr. Alexander Buchmann with Alto Uro in Bern Switzerland to establish the CaverStemTM program in Switzerland, Germany and Austria. We are pleased with the opportunity to work with a highly regarded physician such as Dr. Buchmann to expand CaverStemTM in Europe.
CaverStemTM Clincal Trial: As per our contract with LA BioMed, the results will be made available 12 months after the last patient was enrolled. This will occur the end of August 2018. Once the data is received, analyzed and peer reviewed, the results will be jointly released by our company and LA BioMed.
American Urological Association Regional Conference: We will be exhibiting at this conference in Chicago September 5-9, 2018.
StemSpineTM: This patented technology for the use of stem cells for the treatment of degenerative disc disease represents the entry into a multi-billion dollar market. The StemSpineTM model is the use of stem cells from bone marrow from the as with the CaverStemTM program.
AmnioStemTM: The AmnioStemTM program is meeting our expected development milestones.
Stroke, Medical Wasting, Radiation Toxicity and other patents: Our intellectual property portfolio is meeting our expected milestones and we intend to release information as our progress continues.
Summary: We have faced challenges but we continue to grow our programs strategically and efficiently. We are optimistic with the progress and fundamentals of our company.
We wish to thank our shareholders for their continued support.
Recent CELZ News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/16/2024 04:15:14 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/04/2024 08:46:02 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2024 08:45:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM
Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • BURU • Oct 15, 2024 8:21 AM